Ganli Pharmaceutical Industry: Signs a framework agreement worth 3 billion yuan.

Gan Li Pharmaceutical announced that the company has signed a "Technology Transfer and Supply Agreement" with Fundao Oswaldo Cruz-Bio-Manguinhos and BIOMM, as well as a "Supply Framework Agreement". The "Technology Transfer and Supply Agreement" involves the technology transfer of Ganli insulin as well as the supply of raw materials and injections. The total amount of the "Supply Framework Agreement" is expected to be not less than RMB 3 billion, subject to the actual order amount. The signing of the contract is within the approval authority of the company's general manager and has undergone internal approval procedures. The fulfillment of this contract is expected to have a positive impact on the company's operating performance for 2025 and subsequent years, helping to enhance the overall profitability of the company.